Skip to NavigationSkip to content

Menlo Therapeutics' cough drug fails to meet primary endpoint in phase II trial

Published on 09/10/18 at 11:56am

The Redwood City, California-based late stage biopharmaceutical company Menlo Therapeutics have announced that experimental drug serlopitant has failed to meet its primary endpoint in patients with refractory chronic cough in Phase II trials.

The drug also failed to hit primary and secondary efficacy goals in a Phase II trial studying its use in treating pruritis in adults and adolescents with a history of atopic dermatitis earlier this year.

CEO Steve Basta commented “we do not anticipate further development of serlopitant for the treatment of refractory chronic cough” but added that “we are continuing the clinical development of serlopitant for pruritus associated with various conditions given the two successful Phase II clinical trials in which serlopitant demonstrated a reduction in chronic pruritus and pruritus associated with prurigo nodularis”

The Phase II trial involving 185 patients found that those receiving serlopitant had experienced a 31% less reduction in coughing than those taking a placebo. In a secondary analysis 44% of those taking serlopitant and 54% of those taking a placebo experienced a 30% or greater reduction in coughing after 12 weeks of treatment.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches